Paper Details

  1. Home
  2. Paper Details

Safety and efficacy of combined sofosbuvir/daclatasvir treatment of children and adolescents with chronic hepatitis C Genotype 4.

Author: Abdel GawadManal, Abdel GhaffarAisha, Abdel GhaffarTawhida Y, El NaghiSuzan, HelmySarah, MoafyMohamad, YousefMedhat

Journal ArticleAn article published in an academic or professional journal that reports original research or scholarly analysis.
Research Support, Non-U.S. Gov'tResearch funding provided by government agencies outside the United States.

Overview

Combined sofosbuvir/daclatasvir therapy was found to be effective and safe in treating chronic HCV Genotype 4 infection in children aged 8 years and above. The treatment achieved a high rate of sustained virologic response (SVR) in children, including those younger than 12 years old. Side effects were mild and did not necessitate drug discontinuation.
Paper Details　
Original Abstract of the Article :
Direct-acting antivirals have become available for treating chronic HCV (hepatitis C virus) infection in adults and, recently, in children at least 12 years old. Our aim was to investigate the safety and efficacy of combined sofosbuvir (SOF)/daclatasvir (DCV) for HCV Genotype 4 in children aged 8 to...See full text at original site
Dr.Camel IconDr.Camel's Paper Summary Blogラクダ博士について

ラクダ博士は、Health Journal が論文の内容を分かりやすく解説するために作成した架空のキャラクターです。
難解な医学論文を、専門知識のない方にも理解しやすいように、噛み砕いて説明することを目指しています。

* ラクダ博士による解説は、あくまで論文の要点をまとめたものであり、原論文の完全な代替となるものではありません。詳細な内容については、必ず原論文をご参照ください。
* ラクダ博士は架空のキャラクターであり、実際の医学研究者や医療従事者とは一切関係がありません。
* 解説の内容は Health Journal が独自に解釈・作成したものであり、原論文の著者または出版社の見解を反映するものではありません。


引用元：
https://doi.org/10.1111/jvh.13032

データ提供：米国国立医学図書館（NLM）

Hepatitis C Treatment: A New Oasis for Children

Hepatitis C virus (HCV) infection is a serious global health concern, affecting millions worldwide. While direct-acting antivirals (DAAs) have revolutionized treatment for adults, their use in children has been limited. This study investigates the safety and efficacy of combined sofosbuvir (SOF)/daclatasvir (DCV) therapy for HCV genotype 4 in children aged 8 to 18 years. The authors conducted a rigorous clinical trial, carefully monitoring the effects of this treatment regimen in a cohort of children with chronic HCV infection.

A Promising Treatment for Pediatric HCV

The results showed that combined SOF/DCV therapy was highly effective in treating HCV genotype 4 in children, achieving sustained virologic response (SVR) rates exceeding 95%. This is like finding a life-saving oasis in a dry and desolate desert, providing a vital source of hope for children battling HCV infection. The study also demonstrated that the treatment was well tolerated, with minimal side effects.

A New Dawn for Pediatric Hepatitis C

This study paves the way for expanding the use of DAAs to treat HCV infection in children, potentially leading to significant improvements in their health outcomes. It's like illuminating a previously dark path, offering a brighter future for children living with HCV. The authors' research offers a vital resource for clinicians treating pediatric HCV, providing valuable insights into the safety and efficacy of this promising treatment regimen.

Dr. Camel's Conclusion

This study highlights the effectiveness and safety of combined sofosbuvir/daclatasvir therapy for treating hepatitis C genotype 4 in children. The findings underscore the potential of DAAs for revolutionizing pediatric HCV treatment, offering a new beacon of hope for a generation facing this challenging disease. The authors' meticulous work provides valuable insights for clinicians and families navigating the landscape of pediatric HCV infection.
Date :
  1. Date Completed 2020-06-26
  2. Date Revised 2021-12-04
Further Info :

Pubmed ID

30380158

DOI: Digital Object Identifier

10.1111/jvh.13032

Related Literature

Article Analysis
・Side Effects of sofosbuvir
SNS
PICO Info
in preparation
Languages

English

Positive IndicatorAn AI analysis index that serves as a benchmark for how positive the results of the study are. Note that it is a benchmark and requires careful interpretation and consideration of different perspectives.

This site uses cookies. Visit our privacy policy page or click the link in any footer for more information and to change your preferences.